Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

[email protected]

Sheryl Seapy

Pure Communications

[email protected]


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
07:28pENGIE : Other services
AQ
07:28pTAMILNADU TELECOMMUNICATIONS : High Back Cushioned Type Revolving Chair
AQ
07:28pTAMILNADU TELECOMMUNICATIONS : Set of Water Tank Connection items
AQ
07:28p"Onboard Camera" in Patent Application Approval Process (USPTO 20180095206)
AQ
07:27p"Light Emitting Device, Display Unit, and Image Display Device" in Patent Application Approval Process (USPTO 20180097159)
AQ
07:27pTAMILNADU TELECOMMUNICATIONS : Exercise Cycle
AQ
07:27pTAMILNADU TELECOMMUNICATIONS : Coupling Assembly flexible
AQ
07:27pOFFICE EQUIPMENT : Proposed Purchase of Office Equipment and Furnitures
AQ
07:27pOFFICE EQUIPMENT : Rfq - Office Equipment (Airconditioning Unit)
AQ
07:27pLUXOTTICA : Notice on an Italian newspaper to be published on April 20, 2017
PU
Latest news "Companies"
Advertisement